Ocata Shareholders Hold Out On Astellas Offer
This article was originally published in PharmAsia News
Another tender offer deadline has come and gone for Astellas in its pursuit of Boston's Ocata Therapeutics, but the Japanese firm remains committed to pursuing its quarry.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.